Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 631 - 640 of 785 studies

Cancer and neoplasms

Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in participants with KRAS-Mutant Advanced Solid Tumours (WEF-001-01)

A Multi-Country Observational Chart Review Study to Characterize Treatment Patterns and Clinical Outcomes among Patients with Resectable Gastric or Gastroesophageal Junction Cancer (GALERAS)

Eye

A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects with Stargardt Disease (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene (ASTRA)

Cancer and neoplasms

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Inavolisib Plus A Cdk4/6 Inhibitor And Letrozole Versus Placebo Plus A Cdk4/6 Inhibitor And Letrozole In Patients With Endocrine-Sensitive Pik3ca-Mutated, Hormone Receptor-Positive, Her2-Negative Advanced Breast Cancer (INAVO123)

Defining responses to infection and antibiotic treatment using wearable devices

Cancer and neoplasms

TERZO - A multicentre, open-label, Phase 3, randomised controlled trial of duvelisib versus investigator’s choice of gemcitabine or bendamustine in patients with relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype (SBI-0145-304) (SBI-0145-304 (TERZO))

Cancer and neoplasms

A Randomized, Open-Label, Multicenter, Phase 3 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP versus Polatuzumab Vedotin plus R-CHP in Treatment-naive Participants with GCB Subtype of Diffuse Large B-Cell Lymphoma (DLBCL) (MK2140-011 (waveline-011))

Oral and Gastrointestinal

Prospective non-interventional, phase IV multicentre study to assess the effectiveness, safety and tolerability of elafibranor 80 mg/day in patients with primary biliary cholangitis receiving treatment in a real-world setting. (ELfinity)

Cancer and neoplasms

A Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma (BGB-11417-302 (CELESTIAL-RRMCL))

Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)